Managing DME When Anti-VEGF Response Is Limited

• by Baruch D. Kuppermann, MD, PhD, Michael A. Singer, MD

• March 1, 2026

Semaglutide Linked to NAION Risk

A retrospective database study found a low absolute incidence but higher relative hazard of ischemic optic neuropathy following semaglutide initiation.

• by Andrea Surnit

• May 11, 2026

• 3 min

Evaluation of the safety and neuroprotective properties of the VCP inhibitor ML240 in large-animal and human retinal explants: a preclinical ex vivo investigation

• by Ana-Cristina Almansa-García, Angela Armento, Bowen Cao, Anne-Sophie Petremann-Dumé, Stefano Salmaso, Paolo Caliceti, Cristine Henes, Sylvie Bolz, Ellen Kilger, Daniela Süsskind, Marius Ueffing, Blanca Arango-Gonzalez

• January 10, 2026

Single-cell transcriptomic profiling uncovers pathogenic cellular diversity and potential inflammatory markers in the retinas of STZ-induced diabetic mice

• by Shuai Ouyang, Jingwen Wang, Xiaolan Du, Shouyue Zhang, Shijun Han, Xiaotong Xu, Beichen Ren, Weihong Yu

• April 29, 2026